TARRYTOWN, N.Y., Nov. 3, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) will host a conference call and webcast to discuss its financial results for the third quarter of 2011 on Wednesday, November 9, 2011 at 8:30 a.m. Eastern Time.
To join the conference call, please dial 877-250-8889 (domestic) or 720-545-0001 (international). The access code for the live call is 23210475. An archived replay will be available from 12:00 p.m. ET through November 23 by telephoning 800-871-9012 and entering extension 194206# (domestic), or 641-715-3900 (international) and entering extension 869916#. The live webcast will be available on the Events page of the Company's website and archived for 30 days.
About Progenics
Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) develops innovative therapeutics for patients suffering from cancer and related conditions. Its pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 1 clinical testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics' first commercial product, RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection, is a first-in-class treatment for opioid-induced constipation. It is approved in over 50 countries for patients with advanced illness and licensed to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. is developing the subcutaneous formulation. A U.S. application for approval of RELISTOR to treat OIC in patients with chronic, non-cancer pain is pending; and a phase 3 clinical trial of an oral formulation of methylnaltrexone in this patient population completed enrollment in mid-2011.
Additional information concerning Progenics and its business may be available in press releases or other announcements and public filings made after this release.
The Progenics Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=9678.
(PGNX-G)